Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Alterity Therapeutics ( (ATHE) ) has issued an update.
On February 17, 2025, Alterity Therapeutics Limited announced a new application for the quotation of 1,165,841,830 ordinary fully paid securities as part of a transaction previously communicated to the market. This move, part of a larger placement requiring shareholder approval, suggests an expansion in the company’s capital structure, potentially impacting its market positioning and stakeholder interests.
More about Alterity Therapeutics
Alterity Therapeutics Limited is a development stage enterprise in the biopharmaceutical industry, focusing on the development of therapies for neurodegenerative diseases.
YTD Price Performance: 18.50%
Average Trading Volume: 531,051
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $42.22M
Find detailed analytics on ATHE stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue